Increased Lymphocyte Caspase-3 Activity in Patients with Schizophrenia

Open access

Increased Lymphocyte Caspase-3 Activity in Patients with Schizophrenia

A growing body of evidence indicates that cortical brain cells of schizophrenic patients are vulnerable to apoptosis. As apoptosis is an important mechanism in organism modeling during development, active since the early phase of intrauterine life, it could be involved in the pathogenesis of schizophrenia. To test this hypothesis, caspase-3 activity was determined in peripheral blood mono nuclear cells from 30 patients with schizophrenia and from 30 age and gender matched healthy subjects by a colorimetric commercially available kit. Consistent with increased susceptibility to apoptosis, caspase-3 activity in lymphocytes of patients with schizophrenia was significantly increased (0.111±0.055 μmol/mg protein, p<0.05) in comparison with those in the matched control group (0.086±0.030 μmol/mg protein). The highest activity was obtained in the group showing almost equally positive and negative symptoms (0.159±0.096 μmol/mg protein) and it was significantly higher (p<0.05) compared to the group with a relative predomination of positive symptoms (0.100±0.029 μmol/mg protein). Caspase-3 activity in patients receiving typical antipsychotic drugs (0.124± 0.071 μmol/mg protein) was not significantly different from that in patients treated with atypical antipsychotics (0.104±0.039 μmol/mg protein). To our knowledge to date, this has been the first demonstration that there is a significant increase in caspase-3 activity, determined in native cells, in patients with schizophrenia, indicating a dysregulated apoptotic mechanism in this disease.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Tsuang MT. Schizophrenia: genes and environment. Biol Psychiatry 2000; 47: 210-20.

  • Harrison PJ Owen MJ. Genes or schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003; 361: 417-19.

  • Levinson DF. Molecular genetics of schizophrenia: a review of the recent literature. Curr Opin Psychiatry 2003; 16: 157-70.

  • Gregorio SP Sallet PC Do KA Lin E Gattaz WF DiasNeto E. Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: Preliminary evidence. Psychiatry Res 2009; 165: 1-9.

  • Lewis CM Levinson DF Wise LH DeLisi LE Straub RE Hovatta I et al. Genome scan meta-analysis of schizophrenia and bipolar disorder part II: Schizophrenia. Am J Hum Genet 2003; 73 (1): 34-48.

  • Rehn AE Rees SM. Investigating the neurodevelopmental hypothesis of schizophrenia. Clin Exp Pharmacol Physiol 2005; 32: 687-98.

  • Vankatasubramanian G. Schizophrenia is a disorder of aberrant neurodevelopment: A synthesis of evidence from clinical and structural functional and neuro chemical brain imaging studies. Indian J Psychiatry 2007; 49: 244-9.

  • Benes FM Davidson J Bird ED. Quantitative cytoarchitectural studies of the cerebral cortex of schi zophrenics. Arch Gen Psychiatry 1986; 43: 31-5.

  • Catts VS Catts SV O'Toole BI Frost ADJ. Cancer incidence in patients with schizophrenia and their firstdegree relatives - a meta-analysis. Acta Psychiatr Scand 2008; 117: 323-36.

  • Oken RJ Schulzer M. Schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr Bull 1999; 25: 625-38.

  • Jones EG. Cortical development and thalamic pathology in schizophrenia. Schizophr Bull 1997; 23: 483-501.

  • Benes FM Walsh J Bhattacharyya S Sheth A Berretta S. DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch Gen Psychiaty 2003; 60: 359-64.

  • Coulson E. Cell death and proliferation in mental disorder. PhD Thesis University of Queensland 2006.

  • Jarskog LF Glantz LA Gilmore JH Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 846-58.

  • Yuan J Yankner BA. Apoptosis in the nervous system. Nature 2000; 407: 802-9.

  • Sastry PS Rao KS. Apoptosis and the nervous system. J Neurochem 2000; 74: 1-20.

  • Schlegel J Peters I Orrenius S Miller DK Thornberry NA Yamin TT Nicholson DV. CPP32/apopain is a key interleukin 1 beta converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem 1996; 271: 1841-4.

  • Hasegawa J Kamada S Kamiike W Shimizu S Imazu T Matsuda H Tsujimoto Y. Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis. Cancer Res 1996; 56: 1713-18.

  • Lakhani SA Masud A Kuida K Porter GA Booth CJ Mehal WZ Inayat I Flavell RA. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006; 311: 847-51.

  • Fernando P Brunette S Megeney LA. Neural stem cell differentiation is dependent upon endogenous caspase-3 activity. FASEB J 2005; 19 (12): 1671-3.

  • Aranha MM Sola S Low CW Steer CJ Rodrigues CMP. Caspases and p53 modulate FOXO3A/Id1 signaling during mouse neural stem cell differentiation. J Cell Biochem 2009; 107: 748-58.

  • Kudriashova IV Onufriev MV Kudriashov IE Guliaeva NV. Caspase-3 actvivity in the rat hippocampal slices reflects changes in synaptic plasticity. Ross Fiziol Zh I M Sechenova 2008; 94 (1): 3-13.

  • Catts VS Catts SV McGrath JJ Feron F McLean D Coulson EJ Lutze-Mann LH. Apoptosis and schizophrenia: a pilot study based on dermal fibroblast cell lines. Schizophr Res 2006; 84: 20-8.

  • Jarskog LF Selinger ES Lieberman JA Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 2004; 161: 109-15.

  • Tošić M Ott J Barral S Bovet P Deppen P Gheorghita F Matthey ML Parnas J Preisig M Saraga M Solida A Timm S Wang AG Werge T Cuenod M Do KQ. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006; 79: 586-92.

  • Labbe D Teranishi MA Hess A Bloch W Michel O. Activation of caspase-3 is associated with oxidative stress in the hydropic guinea pig cochlea. Hearing Res 2005; 202: 21-7.

  • Ristić T Ćosić V Vlahović P Deljanin-Ilić M Đorđević BV. Could lymphocyte caspase-3 activity predict atherosclerotic plaque vulnerability? Journal of Medical Biochemistry 2010; 29 (2): 73-7.

  • Rauhala P Lin AM-Y Chiueh CC. Neuroprotection by Snitrosoglutathione of brain dopamine neurons from oxidative stress. FASEB J 1998; 12: 165-73.

  • Mannick JB Schonhoff C Papeta N Ghafourifar P Szibor M Fang K Gaston B. S-nitrosylation of mitochondrial caspases. J Cell Biol 2001; 154: 1111-16.

  • Djordjević VV Stojanović I Stanković-Ferlež D Ristić T Lazarević D Ćosić V Đorđević BV. Plasma nitrite/nitrate concentrations in patients with schizophrenia. Clin Chem Lab Med 2010; 48 (1): 89-94.

  • Saed GM Jiang ZL Fletcher NM Galijasevic S Diamond MP Abu-Soud HM. S-nitrosylation of caspase-3 is the mechanism by which adhesion fibroblasts manifest lower apoptosis. Fertility Sterility 2007; 88: S208-S209.

  • Gilman CP Mattson MP. Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility? Neuromol Med 2002; 2: 197-214.

  • Gylys KH Fein JA Cole GM. Caspase inhibition protects nerve terminals from in vitro degradation. Neurochem Res 2002; 27: 465-72.

  • Ivins KJ Bui ET Cotman CW. Beta-amyloid induces local neurite degeneration in cultured hippo-campal neurons: evidence for neuritic apoptosis. Neurobiol 1998; 5: 365-78.

  • Jarskog LF Gilmore JH Glantz LA Gable KL German TT Tong RI Lieberman JA. Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics. Neuropsychopharmacology 2007; 32: 95-102.

  • Noh JS Kang HJ Kim EY Sohn S Chung YK Kim SU. Haloperidol-induced neuronal apoptosis: a role of p38 and c-Jun-NH2-terminal protein kinase. J Neurochem 2000; 75: 2327-34.

  • German TT Tong RI Gilmore JH Lieberman JA Jarskog LF. Regulation of apoptosis by typical and atypical antipsychotics in rat frontal cortex. Biol Psychiatry 2004; 55: 214S.

  • Qing H Xu H Wei Z Gipson K Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci 2003; 17: 1563-70.

  • Miyaoka T Yasukawa R Yasuda H Hayashida M Inagaki T Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008; 31: 287-92.

Journal information
Impact Factor

IMPACT FACTOR 2018: 2.000
5-year IMPACT FACTOR: 1.075

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 246 135 2
PDF Downloads 80 60 0